We prepare mg to multi-g amounts of fully characterized peptides for research. Most syntheses are achieved using solid-phase resin and Fmoc chemistry whilst solution-phase approach is utilized where appropriate for more demanding synthesis or special structural features. We further purify your peptides using reversed-phase HPLC to different levels of purities. We will assist you and recommend the optimum purity level required for your particular application. Peptides are sold for in vitro research use only and they are not intended for medical or diagnostics applications.
The table below describes our classical, most frequently requested syntheses. Please contact us with your sequence(s), amount and purity level and we will always respond with a very competitive offer.
synthesis scales (mg)
|(I)||2 mg (minimum amount)|
|(II)||5 mg to 30 mg in increments of 5 mg|
|(III)||30 mg to 100 mg in increments of 10 mg|
|(IV)||0.1 g to 1 g in increments of 50 mg|
|(V)||1 g to 10 g in increments of 500 mg|
|Purity levels:||>70%, >80%, >90%, >95% and >99%|
|Analytical Data:||HPLC trace (220 nm), mass spectrum (EI, MALDI-TOF) & dissolution conditions|
|Peptide Length:||Standard:5-30 aa ; Routine: 31-60 aa ; Maximum length about 100 aa|
|Structure:||Unblocked termini (i.e. NH2- and -COOH ends)|
|Counter ions:||Standard: Trifluoroacetate (tfa); Option: acetate or chloride|
HPLC purification options include guaranteed purities >70%, >80%, >90%, >95% and a unique ultra-pure >99% grade for demanding experiments.
Purification is performed by preparative or semi-preparative reversed-phase HPLC. We typically use C8 or C18 columns with linear gradients of acetonitrile in 0.1% aqueous tfa with UV monitoring at 220 nm.
HPLC elution may be monitored with UV detector set at longer wavelength for peptides containing aromatic amino acids (Figure 2).
The crude peptide synthesis contains by-products resulting from failed coupling cycles (i.e. truncated chains), and further oxidation, modification, or hydrolysis of side chains arising during cleavage and deprotection. The extent of impurities varies with peptide length and primary sequence.
Depending upon your specific application we would recommend purification levels along the following guidelines.
Experimental applications and recommended purity levels
|Wide range peptide screen ; Polyclonal antibodies production; preliminary library screenings; higher levels should be considered for peptides > 20aa.|
|Biochemical screening assays ; Qualitative immunoassays (ELISA, competition, depletion…) ; Polyclonal antibodies production with long peptides; |
|Initial bioassays of candidate peptide ; Polyclonal mono-specific antibodies; affinity column making; structure-activity studies; qualitative biochemical assays (enzyme activity, specificity…).|
|Quantitative immunoassays (ELISA, competition, depletion…); quantitative biochemical assays (enzyme activity, kinetics…); generally recommended with modified peptides; preliminary structural analysis (NMR,…).|
|Purity >99%, ultra-pure|
|Sensitive bioassays; cell culture assays; quantitative bioassays; structural studies (Crystallography, NMR,…).|
Our peptides are normally synthesized with unblocked termini:
N-terminal amine and C-terminal carboxyl groups.
The pKa values of the terminal alpha-amino group and the carboxylic acid group indicates that the peptide ends are generally electrically charged at physiological pH.
In some instances, it may be preferable to neutralize these electric charges using capping groups. To that effect, peptide ends are often modified by:
N-terminal acetylation and/or C-terminal amidation.
N-acetyl and C-amide closely mimic internal sequences as they have uncharged ends. In addition, these blocking groups improve resistance to enzymatic degradation. It should be noted that as expected, this charge neutralization also often results in deacreased solubility.
Peptides are charged molecules. Standard reversed-phase HPLC purification allows for the isolation of pure peptides that are further freeze-dried yielding peptides preparations that comprise trifluoroacetate (= tfa = CF3COO-) as counterion.
TFA exchange services
Some applications require the removal of tfa. We offer ion exchange option to acetate (CH3COO-) or chloride (Cl-) salts.
We recognize that quality and reliability are central to our customers. As a result no peptide leaves our laboratories unless it has fully complied with our stringent QC standards every step of the process. Your delivered peptides are 100 % guaranteed.
Every peptide is supplied as a stable lyophilized powder with comprehensive documentation. Standard synthesis report includes analytical HPLC trace verifying purity, a mass spectrum ensuring integrity of the desired full-length peptide and dissolution conditions. Lead time will vary with length, scale, purity, and modifications ordered. Our average turn around is shown in the table below, for standard synthesis scales and purities. Our customers are well advised when synthesis difficulties are encountered and product dispatch is delayed.
|Synthesis||25 mg, >70%||25 mg, >80%||25 mg, >90%||25 mg, >95%||25 mg, >99%|
|Average (*)||approx. 2 weeks||approx. 2 - 3 weeks||approx. 2 - 3 weeks||approx. 2-3 weeks||approx. 3 weeks|